JLJiangping Liu

Jiangping Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jiangping Liu has a total of 58 co-authors. Here are the top co-authors by number of shared publications:

  • Hui Chao

    College of Chemistry and Materials Science, State Key Laboratory of Bioactive Molecules and Druggability Assessment Jinan University Guangzhou P. R. China

    15 shared publications
  • Liangnian Ji

    MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, Sun Yat-Sen University, Guangzhou, 510275, P. R. China

    13 shared publications
  • Yu Chen

    MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, Sun Yat-Sen University, Guangzhou, P. R. China

    9 shared publications
  • Chengzhi Jin

    MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, Sun Yat-Sen University, Guangzhou, P. R. China

    7 shared publications
  • Ruilin Guan

    MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, Sun Yat-Sen University, Guangzhou, P. R. China

    6 shared publications
  • Guanying Li

    Department of Biophysics School of Basic Medical Sciences Health Science Centre Xi'an Jiaotong University Shaanxi 710061 P. R. China

    5 shared publications

Latest Publications

  • Open Access

    A Concerted Redox‐ and Light‐Activated Agent for Controlled Multimodal Therapy against Hypoxic Cancer Cells

    by Jiangping Liu, Andrew W. Prentice, Guy J. Clarkson, Jack M. Woolley, Vasilios G. Stavros, Martin J. Paterson, Peter J. Sadler

    Hypoxia represents a remarkably exploitable target for cancer therapy, is encountered only in solid human tumors, and is highly associated with cancer resistance and recurrence. Here, a hypoxia‐activated mitochondria‐accumulated Ru(II) polypyridyl prodrug functionalized with conjugated azo (Az) and nitrogen mustard (NM) functionalities, RuAzNM, is reported. This prodrug has multimodal theranostic properties toward hypoxic cancer cells. Reduction of the azo group in hypoxic cell microenvironments gives rise to the generation of two primary amine products, a free aniline mustard, and the polypyridyl RuNH 2 complex. Thus, the aniline mustard triggers generation of reactive oxygen species (ROS) and mtDNA crosslinking. Meanwhile, the resultant biologically benign phosphorescent RuNH 2 gives rise to a diagnostic signal and signals activation of the phototherapy. This multimodal therapeutic effect eventually elevates ROS levels, depletes reduced nicotinamide adenine dinucleotide (NADH) and adenosine triphosphate (ATP), and induces mitochondrial membrane damage, mtDNA damage, and ultimately cell apoptosis. This unique strategy allows controlled multimodal theranostics to be realized in hypoxic cells and multicellular spheroids, making RuAzNM a highly selective and effective cancer‐cell‐selective theranostic agent (IC 50 = 2.3 µ m for hypoxic HepG2 cancer cells vs 58.2 µ m for normoxic THL‐3 normal cells). This is the first report of a metal‐based compound developed as a multimodal theranostic agent for hypoxia.


  • A mitochondrion-targeted BODIPY-Ir(iii) conjugate as a photoinduced ROS generator for the oxidative destruction of triple-negative breast cancer cells

    by Liping Qiao, Jiangping Liu, Shi Kuang, Xinxing Liao, Junfeng Kou, Liangnian Ji, Hui Chao

    Photodynamic therapy (PDT) provides an alternative option to root out localized triple-negative breast cancer (TNBC) and has been experiencing a surge of research interest over recent years. In this study, we put forward a paradigm of designing novel transition metal-based PSs with the following characteristics: favorable cell-permeability, significant light-harvesting ability and prominent ROS yield. A novel BODIPY-Ir(III) conjugate has been designed as a photoinduced ROS (1O2, ˙OH and ˙O2 −) generator. BODIPY-Ir is highly photoactive in subduing cancer cells in the PDT regimen with PI values ranging from 172 to 519 and EC50 in the nanomolar regime. Among various cancerous cell lines, TNBC was especially sensitive to BODIPY-Ir-mediated PDT, with a stunning EC50 value of 4.32 nM (PI = 519) under a moderate flux of visible-light irradiation (500 nm, 10.5 mW cm−2). BODIPY-Ir mainly accumulates in mitochondria and induces cell apoptosis under irradiation. Furthermore, the nanomolar antiproliferative activity of BODIPY-Ir is retained under hypoxia (2.5% O2). This work sheds light on instilling the O2-independent type I mechanism and conferring a red-shift absorption to metal-based PSs which fundamentally facilitate the clinical translation of PSs.


  • Robust Packing of a Self‐Assembling Iridium Complex via Endocytic Trafficking for Long‐Term Lysosome Tracking

    by Chengzhi Jin, Guanying Li, Xia Wu, Jiangping Liu, Weijun Wu, Yazhou Chen, Toshio Sasaki, Hui Chao, Ye Zhang

    Live cell imaging of lysosome positioning and motility is critical to studying lysosome status and function for pharmacological interventions. To create a super stable lysosomal probe for long‐term live cell imaging, we have designed and synthesized an aromatic‐peptide‐conjugated cyclometalated iridium(III) complex that emits light via π–π stacking oriented self‐assembly in water at extremely low concentration. Through endocytic trafficking, self‐assemblies are transformed from nanoparticles into sturdily packed networks that are stabilized in lysosomal acidic environment. Upon short time/low dose treatment of the iridium complex at passage 0, live cell lysosomal tracking is applicable beyond the 14th passage of cells with high labelling rate and a mild decline in luminescence intensity. The illuminated lysosomes are trackable using super‐resolution imaging to study their response to cellular processes.


  • Rational design of a lysosome-targeting and near-infrared absorbing Ru(ii)–BODIPY conjugate for photodynamic therapy

    by Liping Qiao, Jiangping Liu, Yunhong Han, Fangmian Wei, Xinxing Liao, Cheng Zhang, Lina Xie, Liangnian Ji, Hui Chao

    A Ru(II)–BODIPY conjugate has been rationally designed and exhibits an intense absorption in the NIR region to boost lysosome-targeted PDT in vitro and in vivo. The advantages of Ru(II) and BODIPY were successfully instilled into the conjugate to yield highly effective PDT efficacy against malignant melanoma A375 cells (PI = 3448) and A375 mice xenografts.


  • A self-assembled Ru–Pt metallacage as a lysosome-targeting photosensitizer for 2-photon photodynamic therapy

    by Zhixuan Zhou, Jiangping Liu, Juanjuan Huang, Thomas W. Rees, Yiliang Wang, Heng Wang, Xiaopeng Li, Hui Chao, Peter J. Stang

    Significance: Photodynamic therapy (PDT) is an emerging treatment method for various types of diseases. In PDT, photosensitizers absorb light of appropriate energy and then convert oxygen into highly reactive oxygen species that destroy malignant cells. Photosensitizers with 2-photon absorption bring benefits such as increased penetration depth with near-infrared light excitation and reduced photodamage to healthy tissues. Herein, we describe the use of molecular self-assembly for a metallacage with strong 2-photon absorption by combining multiple Ru(II) complexes with Pt(II) building blocks via coordination. The metallacages were encapsulated in a polymer to form nanoparticles which, upon internalization into cells, accumulate in the lysosomes leading to high photocytoxicity. In vivo studies demonstrated the outstanding therapeutic performance of the nanoparticles in 2-photon PDT.


  • Endoplasmic reticulum targeted cyclometalated iridium(iii) complexes as efficient photodynamic therapy photosensitizers

    by Bo Yuan, Jiangping Liu, Ruilin Guan, Chengzhi Jin, Liangnian Ji, Hui Chao

    The endoplasmic reticulum (ER) is an indispensable organelle that undertakes the synthesis and export of proteins and membrane lipids. Subtle interferences of the ER redox signaling pathway are very likely to cause ER-stress induced apoptosis. In view of this, we herein present a series of ER-targeted Ir(III) complexes (Ir1–Ir3) as photodynamic therapy (PDT) photosensitizers with a gradually extended conjugation area in the main ligand, and study the correlation between the conjugation area and PDT performance. The results showed that all of these complexes can accumulate in the ER and effectively induce cell apoptosis after PDT therapeutics (405 nm, 6 J cm−2) by an ER stress mechanism, and both their singlet oxygen quantum yields and cytotoxicities increase as the conjugation area extends. All complexes showed PDT efficacy towards different cancer cell lines. Among them, Ir2 exhibited the highest PI value (94.3) against A549 cells with an IC50 down to 0.65 μM. In addition, the post PDT ER-stress induced apoptosis along with the efflux of Ca2+ from the ER system in A549 cells in a short period of time (45–90 min) with the pretreatment of Ir2 was demonstrated. All of these results indicate the promising potential of Ir2 as an effective PDT photosensitizer.


  • Heterometallic Ru–Pt metallacycle for two-photon photodynamic therapy

    by Zhixuan Zhou, Jiangping Liu, Thomas W. Rees, Heng Wang, Xiaopeng Li, Hui Chao, Peter J. Stang

    Significance: Photodynamic therapy is a noninvasive medical procedure in which malignant tissue is damaged by reactive oxygen species generated from targeted light irradiation on a photosensitizer. Herein, we incorporate an Ru(II)-based two-photon photosensitizer into a macrocyclic structure via coordination-driven self-assembly. Properties favorable for photodynamic therapy arise upon formation of the metallacycle, including near-infrared luminescence, strong two-photon absorption, high reactive oxygen species generation efficiency, and selective accumulation in mitochondria and nucleus that are hypersensitive to reactive oxygen species, resulting in good photodynamic therapy efficacy in both in vitro and in vivo investigations. This study shows that supramolecular coordination complexes provide a platform for efficient tuning on the photophysical and biological properties of molecules with biomedical interest.


  • Harnessing ruthenium(II) as photodynamic agents: Encouraging advances in cancer therapy

    by Jiangping Liu, Chen Zhang, Thomas W. Rees, Libing Ke, Liangnian Ji, Hui Chao


  • Enhanced cancer therapy by the marriage of metabolic alteration and mitochondrial-targeted photodynamic therapy using cyclometalated Ir(iii) complexes

    by Jiangping Liu, Chengzhi Jin, Bo Yuan, Yu Chen, Xingguo Liu, Liangnian Ji, Hui Chao

    A series of DCA-Ir(iii) co-drug complexes were demonstrated to act in synergy by sensitizing cancer cell for PDT to achieve cancer-specifically enhanced two-photon PDT in the hypoxic muticellular tumor spheroids.


  • Fluorinated cyclometalated iridium( iii ) complexes as mitochondria-targeted theranostic anticancer agents

    by Miao Ouyang, Leli Zeng, Huaiyi Huang, Chengzhi Jin, Jiangping Liu, Yu Chen, Liangnian Ji, Hui Chao

    Six cyclometalated iridium(III) complexes bearing different numbers of fluorine atoms were synthesized. These complexes demonstrated much better anti-proliferation activities towards five tumour cell lines than the widely used clinical chemotherapeutic agent cisplatin. Moreover, the anti-proliferation activities were correlated to the number of substituted fluorine atoms. Colocalization and inductively coupled plasma-mass spectrometry (ICP-MS) indicated that this series of complexes could penetrate cell membranes rapidly and preferentially target mitochondria. Manifesting high selectivity between tumour cells and normal cells and remarkable sensitivity to a cisplatin-resistant cell line (A549R), complex Ir6 was successfully developed as a novel anticancer agent (with IC50 values of 0.5 ± 0.1 μM for HeLa, 1.1 ± 0.2 μM for HepG2, 1.5 ± 0.3 μM for BEL-7402, 0.8 ± 0.1 μM for A549, and 0.7 ± 0.2 μM for A549R cell lines). Further mechanism studies including mitochondrial membrane potential depolarization and caspase 3/7 activation revealed that Ir6 induced apoptosis via mitochondrial pathways. These results demonstrated that complex Ir6 might be a promising candidate as a mitochondria-targeted theranostic anticancer agent.